Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

KU Leuven and life sciences institute VIB officially unveiled Belgium-based drug development business Augustine Therapeutics today with €4.2m ($4.7m) in seed funding to target neuromuscular disorders such as Charcot–Marie–Tooth (CMT) disease. The money was supplied by VIB and its affiliate V-Bio Ventures venture fund, as well as KU Leuven-backed seed vehicle Gemma Frisius Fund, Flemish…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.